The future of CGP is promising, with ongoing advancements in sequencing technologies and bioinformatics. Emerging approaches such as liquid biopsies are making it possible to perform CGP using blood samples, which is less invasive than traditional biopsies. Additionally, the integration of CGP data with artificial intelligence and machine learning could enhance the accuracy and utility of genomic profiling, leading to more precise and personalized cancer treatments.
